Results 81 to 90 of about 9,247 (168)

Mitigating Teclistamab Toxicity: Prophylactic Tocilizumab and Timing of Immunoglobulin Replacement Therapy in a Nationwide Cohort

American Journal of Hematology, Volume 101, Issue 8, Page 2081-2085, August 2026.
Astrid Hundebøll Torpe, Jonathan Thorsen, Gustav Mathiasen, Katrine Fladeland Iversen, Sarah Farmer, Thomas Lund, Charlotte Toftmann Hansen, Lene Kongsgaard Nielsen, Nicolai Grønne Dahlager Jørgensen, Maja Ølholm Vase, Elena Manuela Teodorescu, Morten Salomo, Christina Wennerström, Tobias S. Slørdahl, Agoston Gyula Szabo   +14 more
wiley   +1 more source

Choroidal Leakage during Daratumumab Therapy: A Desensitization‐Based Strategy for Treatment Continuation in Relapsed/Refractory Multiple Myeloma

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Background Daratumumab is widely used in relapsed/refractory multiple myeloma, but ocular adverse events are rare and not well‐characterized. Case Presentation A 68‐year‐old woman developed acute blurred vision during the second day of her first daratumumab infusion.
Metban Mastanzade, Zafer Cebeci, Kıvanç Koruk, Kerem Yiğit, Gül Beste Can, Sevgi Kalayoglu Beşışık   +5 more
wiley   +1 more source

Persistence to Multiple Myeloma Treatments Given at First Relapse—Results From the Australian Real‐World OPTIMISE Study

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Background Daratumumab became publicly available in Australia in 2021 in combination with bortezomib and dexamethasone (DVd), as a second‐line (2L) therapy for multiple myeloma (MM). We evaluated real‐world persistence to any MM treatment after first relapse before and after DVd availability using the Pharmaceutical Benefits Scheme 10% sample ...
Felix Buescher, Steve Su, Ben Waterhouse, Cletus Pinto   +3 more
wiley   +1 more source

Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 8, August 2026.
The graphic summarizes the design principles, intracellular trafficking, clinical progress, challenges, and future directions of antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs). ADCs consist of a tumor‐targeting antibody, a chemical linker, and a potent payload, whereas PDCs use peptide ligands to deliver cytotoxic, radionuclide, or ...
Ruxi Zheng, Shuiquan Li, Zhigang Zhang, Mengke Niu, Jing Fei, Jiaojiao Zhang, Jianwei Zhou, Kongming Wu, Ming Yi, Tianye Li   +9 more
wiley   +1 more source

Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 4, Page 573-583, August 2026.
RVD with weekly bortezomib dosing in real‐world newly diagnosed transplant‐ineligible myeloma shows comparable efficacy and reduced toxicity compared to twice‐weekly trial protocols. ABSTRACT Background Lenalidomide, bortezomib, and dexamethasone (RVD) remains a standard of care regimen for newly diagnosed multiple myeloma in centers without access to ...
Samantha Kurniawan, Angela Hwang, Nicole Wong Doo, Tracy King, Christian Bryant, Jennifer Zhang, Kristina Whelan, Parisa Fani‐Molky, Giselle Kidson‐Gerber, Annmarie Bosco, Nada Hamad, Gurdeep Parmar, Fiona Kwok, Sam Lai, Silvia Ling, P. Joy Ho, Georgia McCaughan, Adam Bryant   +17 more
wiley   +1 more source

Cesni‐cel (ARI0002h) in ultra‐high‐risk multiple myeloma with plasma cell leukaemia or central nervous system involvement

British Journal of Haematology, Volume 209, Issue 2, Page 610-620, August 2026.
ARI0002h induced response in 15/17 patients with plasma cell leukaemia (PCL)/central nervous system (CNS)‐multiple myeloma (MM) (87% achieved ≥ very good partial response [VGPR]) with a median progression‐free survival (PFS)/overall survival (OS) of 10.5 and 15.9 months respectively.
Carlos Jimenez‐Mira, Natalia Tovar, Núria Martínez‐Cibrián, Verónica González‐Calle, Nil Albiol, Nieves López‐Muñoz, Aina Oliver‐Caldés, Azucena González, José Miguel Mateos, Marta Español‐Rego, Laura Rosiñol, Manel Juan, Paola Charry, José María Sanchez‐Pina, Sergio Navarro, Daniel Munárriz, Lucía López‐Corral, Valentín Ortiz‐Maldonado, Sara Varea, Eulalia Olesti, Julio Delgado, Álvaro Urbano‐Ispizua, Joaquín Martínez‐López, María Victoria Mateos, Luis Gerardo Rodríguez‐Lobato, Carlos Fernández de Larrea   +25 more
wiley   +1 more source

Spontaneous Acute Left‐Sided Abdominal Pain in a Patient With AL Amyloidosis

eJHaem, Volume 7, Issue 4, August 2026.
Shahzil Abdur Rehman Malik, Utkarsh Goel, Jason Valent, Faiz Anwer   +3 more
wiley   +1 more source

A Simulation‐Based Assessment of Dosage Regimen Appropriateness for Multiple Myeloma Medicines Reflecting Demographic and Ethnic Differences

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Bridging studies are often waived for orphan diseases such as multiple myeloma (MM) due to challenges in conducting clinical trials in small and heterogeneous populations. However, demographic and regional differences between trial participants and Asian populations may influence drug exposure and response.
Minji Kang, Suein Choi, Sung‐Soo Park, Sungpil Han, Seunghoon Han   +4 more
wiley   +1 more source

Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab‐Based Regimens

European Journal of Haematology, Volume 117, Issue 2, Page 409-421, August 2026.
ABSTRACT Gain/amplification of chromosome arm 1q (+1q) is among the most frequent cytogenetic abnormalities (CAs) in multiple myeloma (MM), and a recognized marker of poor prognosis, now integrated into modern risk stratification systems. The advent of anti‐CD38 monoclonal antibodies, particularly daratumumab, has significantly improved outcomes ...
Emiliano Barbieri, Laura Arletti, Micol Quaresima, Elena Rivolti, Luca Braglia, Cecilia Fabiano, Adriana Maria Rita Alfano, Monia Rinaldini, Veronica Bizzarri, Chiara Cattani, Maria Marinelli, Barbara Gamberi   +11 more
wiley   +1 more source

Light Chain Crystalline Proximal Tubulopathy and Podocytopathy With Staining for Both Light and Heavy Chain Immunoglobulin

Nephrology, Volume 31, Issue 8, August 2026.
ABSTRACT A 69‐year‐old male patient presented with weight loss and proteinuria. His medical history included papillary thyroid carcinoma. Laboratory findings showed proteinuria and high κ light chain levels in both urine and serum. Bone marrow aspiration revealed plasma cell myeloma of the IgA‐κ type.
Seoyoung Choi, Kyung Chul Moon
wiley   +1 more source